23:31:57 EDT Mon 13 May 2024
Enter Symbol
or Name
USA
CA



Cognetivity Neurosciences Ltd
Symbol CGN
Shares Issued 86,988,124
Close 2023-06-23 C$ 0.295
Market Cap C$ 25,661,497
Recent Sedar Documents

Cognetivity to issue shares for debt

2023-06-23 17:34 ET - News Release

Mr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES ANNOUNCES ISSUANCE OF COMMON SHARES PURSUANT TO DEBT SETTLEMENTS, CONSULTING AGREEMENT AND ADVISORY AGREEMENTS

Cognetivity Neurosciences Ltd. has entered into debt settlement agreements with certain creditors of the company to issue an aggregate of 168,782 common shares in the capital of company at a deemed price of 30 cents per debt share to settle an aggregate of approximately $50,634.72 of outstanding debt.

In addition, in accordance with the terms of a consulting agreement with an arm's-length consultant, the company will issue 100,000 common shares in the capital of the company at a deemed price of 30 cents per consulting share for payment of $30,000, representing work completed from Jan. 1, 2023, to March 31, 2023.

Also, in accordance with the terms of certain advisory agreements with arm's-length advisers, the company will issue an aggregate of 50,000 common shares in the capital of the company at a deemed price of 30 cents per advisory share to the advisers in accordance with the terms of the advisory agreements.

The debt shares, consulting shares and advisory shares are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

Closing of the debt settlement and the issuance of consulting shares and advisory shares are subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, the United Kingdom, Europe and the Middle East, with regulatory approval in other regions expected in 2023.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.